Blockade of exosome release alters HER2 trafficking to the plasma membrane and gives a boost to Trastuzumab.
Reza HosseiniLeila Asef-KabiriHamzeh SarvnazAlireza GhanavatinejadFatemeh RezayatNahid EskandariMohammad Esmaeil AkbariPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2022)
Based on our findings, HER2+ exosomes may benefit tumor progression by dually suppressing Trastuzumab-induced tumor growth inhibition and cytotoxicity of NK cells. It seems that concomitant blocking of exosome release might be an effective approach for improving the therapeutic effects of Trastuzumab, and potentially other HER2-directed mAbs. In addition, the exosome secretion pathway possibly contributes to the HER2 trafficking to plasma membrane, since the blockade of exosome secretion decreased surface HER2 levels.